Sermorelin
The most clinically validated GH secretagogue — FDA-approved, longest safety record, physiological pulsatile GH release.
Research facts
| Half-life | ~11 minutes |
|---|---|
| Route | SubQ / IM |
| Typical dose | 200–500 mcg |
| Frequency | Once nightly (fasted) |
| Solvent | Bacteriostatic water |
| pH | 5.5–7.0 |
| Stability | 30 days at +4°C |
Mechanism of action
Sermorelin comprises the first 29 amino acids of endogenous GHRH — the portion responsible for full receptor binding and GH secretion stimulation at the anterior pituitary somatotroph cells. It has the longest clinical track record of any GH secretagogue, having been FDA-approved as Geref for paediatric GH deficiency diagnosis and treatment.
The ultra-short half-life (~11 minutes) means the GH pulse is inherently self-limiting. The pituitary responds with a physiological burst, then normalises — preserving the hypothalamic-pituitary feedback axis without chronic overstimulation. This self-regulating property is why Sermorelin is preferred over exogenous HGH by many longevity practitioners: it works with endogenous physiology rather than bypassing it.
Andrew Huberman has publicly disclosed using Sermorelin before bed for deeper sleep and faster recovery. Bedtime dosing aligns with the natural GH surge during slow-wave sleep, potentially amplifying sleep quality and overnight tissue repair.
Documented effects (research-model)
- Physiological pulsatile GH stimulation — works with the axis, not around it
- Deep sleep (slow-wave) quality enhancement
- Body composition improvement via IGF-1 elevation
- Recovery acceleration via overnight GH pulse
- Anti-ageing endocrine support
- Bone density research in GH-deficient populations
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard | 200–300 mcg before bed | Once nightly, fasted 2h | 12 weeks on / 4 off | 9mg / 3mL BAC water |
| Advanced | 300–500 mcg | Nightly, 3–5 nights/week | Ongoing cycles | 9mg / 3mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Ipamorelin HIGH
The Clinical GH Stack — Sermorelin (FDA-approved GHRH) + Ipamorelin (clean GHRP). Best clinical safety record in GHRH+GHRP class. - BPC-157 MODERATE
Systemic GH pulse for overnight recovery + localised tissue repair.
Myths & misconceptions
Evidence gaps
- Post-approval research on anti-ageing applications is mostly small-scale observational.
- Optimal dosing for body composition vs. sleep enhancement vs. GH deficiency replacement has not been formally compared.
Safety notes
Best-characterised safety profile of GH secretagogues. FDA clinical approval history for paediatric GH deficiency. Never placed on FDA restricted list. Monitor IGF-1 annually.
Biomarkers to monitor
Primary-source citations
- PMID 7593434 — Sermorelin: a review of its use in GH deficiency treatment (BioDrugs. 1997)
- PMID 12020792 — Growth hormone-releasing hormone in aging and anti-aging (Peptides. 2002)
Frequently asked
What is Sermorelin?
Sermorelin (GHRH(1-29) — FDA-Approved GH Secretagogue) is a research compound classified in our library as Tier A — Reproducible human RCT data.. The most clinically validated GH secretagogue — FDA-approved, longest safety record, physiological pulsatile GH release.
What is the evidence tier for Sermorelin?
We classify Sermorelin as Tier A: Reproducible human RCT data. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Sermorelin?
For Sermorelin, typical research dose is 200–500 mcg, route is SubQ / IM, half-life is ~11 minutes. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does Sermorelin stack well with?
Sermorelin stacks well with Ipamorelin. The Clinical GH Stack — Sermorelin (FDA-approved GHRH) + Ipamorelin (clean GHRP). Best clinical safety record in GHRH+GHRP class.
Is Sermorelin safe?
Best-characterised safety profile of GH secretagogues. FDA clinical approval history for paediatric GH deficiency. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.